CareDX (CDNA) is a precision medicine company that offers testing services, products and digital solutions along a patient’s pre- and post-transplant journey, Hilary Kramer, growth stock specialist and editor of GameChangers.

The company derives most of its revenues from testing services, primarily its AlloSure Kidney test, which is a donor-derived cell-free DNA solution for kidney transplant patients.

In addition, AlloSure can help health care providers and their patients better manage their long-term care following a kidney transplant.

AlloSure can improve patient care by helping health care providers reduce the use of invasive biopsies. They can also determine the appropriate dosage level of immunosuppressants.

AlloSure’s effectiveness was verified in a 14-center prospective study and is currently being used in 115 transplant centers. Patients can get the cost for this treatment fully reimbursed through Medicare.

Similarly, AlloMap Heart, a gene expression solution for heart transplant patients, is also fully reimbursable. During 2019, the company performed more than 49,000 commercial AlloSure and AlloMap tests.

The company’s product division manufactures and sells products that increase the chance of a successful transplant by facilitating a better match between a solid organ or stem cell donor and a recipient.

The company's long-term potential remains huge. So, while the stock is not cheap at over 50x 2021 EPS estimates of $0.65, the company’s significant growth history and potential make it a solid choice at the present time.

Subscribe to GameChangers here…